U.S. Stock Movement | Argenx (ARGX.US) pre-market rises over 10% as its autoimmune myositis drug Vyvgart reaches primary endpoint in Phase III study.

According to Zhito Finance APP, pre-market trading on Monday saw shares of the European biotechnology company Argenx (ARGX.US) soar by 10.38%. The company announced on Monday that its autoimmune myositis drug Vyvgart achieved its primary endpoint in Phase III studies.